In patients with previously treated mCRPC, the addition of 177Lu-PSMA-617 to standard of care resulted in improvements in health-related quality of life and time to worsening of pain and first symptomatic skeletal events, in addition to the previously reported OS and rPFS benefits.
On-demand webcast of a live webinar on the urologist’s role in testing and using PARP inhibitors for prostate cancer, from Clinical Care Options (CCO)
Experts provide their thoughts on key data in breast, gynecologic, renal cell, urothelial, lung, hepatobiliary, and skin cancers presented at the 2022 ESMO Congress, from Clinical Care Options (CCO)
On-demand webcast: Brenda Martone, MSN, ANP-BC, AOCNP, on best nursing practices for metastatic prostate cancer, from Clinical Care Options (CCO)
Downloadable slides from oncology nurse experts on nursing considerations for metastatic prostate cancer, from Clinical Care Options (CCO)